Factor V Test at Chughtai Lab

Factor V Test at Chughtai Lab

The Factor V test is a highly specialized diagnostic investigation performed to evaluate the coagulation profile and genetic predisposition to thrombotic disorders in patients. Factor V, also known as proaccelerin or labile factor, is an essential glycoprotein synthesized primarily in the liver. It circulates in an inactive form in the blood and acts as a critical cofactor in the coagulation cascade. Upon activation, Factor V interacts with activated Factor X to form the prothrombinase complex, which rapidly converts prothrombin to thrombin, leading to the formation of a stable fibrin clot. A deficiency or mutation in this factor can lead to severe clinical consequences, ranging from life-threatening bleeding episodes to recurrent, abnormal blood clots. Chughtai Lab, a premier diagnostic network in Pakistan, offers comprehensive Factor V testing, including both Factor V Activity Assays and molecular testing for the Factor V Leiden mutation, utilizing state-of-the-art automated platforms and molecular diagnostic technologies.

Understanding the clinical importance of Factor V is vital for managing patients with unexplained thromboembolic events or bleeding tendencies. The Factor V Activity Assay measures the functional capacity of the Factor V protein in the plasma, helping hematologists diagnose rare congenital deficiencies (parahemophilia) or acquired deficiencies due to severe liver disease, disseminated intravascular coagulation (DIC), or autoimmune inhibitors. Conversely, the Factor V Leiden test is a genetic assay that identifies a specific point mutation in the F5 gene (G1691A). This mutation alters the Factor V protein structure, making it resistant to inactivation by Activated Protein C (APC). Consequently, the mutated Factor V remains active longer, promoting excess thrombin generation and significantly increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). By providing highly accurate and timely results, Chughtai Lab assists clinicians in tailoring anticoagulant therapies, assessing gestational risks, and implementing preventive measures for high-risk patients.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the clinical accuracy of the Factor V test, particularly for activity assays which are highly sensitive to pre-analytical variables. Patients undergoing a Factor V test at Chughtai Lab should observe the following guidelines:

• Medication Disclosure: It is critical to inform the healthcare provider and laboratory staff of all medications currently being taken, especially anticoagulants such as warfarin, heparin, low-molecular-weight heparin (LMWH), or direct oral anticoagulants (DOACs) like rivaroxaban and apixaban, as these can significantly interfere with coagulation activity assays.
• Fasting Requirements: For a standard Factor V Activity Assay or Factor V Leiden genetic test, strict fasting is generally not required. However, patients may be advised to avoid fatty meals immediately before the blood draw to prevent lipemia, which can interfere with optical detection systems used in coagulation analyzers.
• Hydration: Staying well-hydrated by drinking adequate amounts of water prior to the procedure is highly recommended, as it makes venipuncture easier and ensures a smooth sample collection process.
• Timing of the Test: If the test is being performed to monitor or investigate a recent thrombotic event, it is often scheduled after the acute phase has resolved and temporary anticoagulant therapy has been completed, unless otherwise directed by the treating physician.
• Stress and Activity: Patients should avoid strenuous physical exercise and extreme emotional stress immediately before the blood collection, as these factors can transiently alter coagulation factor levels.

During the Procedure

The collection of the blood sample for the Factor V test is a quick and routine outpatient procedure performed by experienced phlebotomists at Chughtai Lab collection centers. The process involves the following clinical steps:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity using standard protocols and confirm the specific test requested (Factor V Activity or Factor V Leiden Mutation).
• Positioning: The patient is comfortably seated or reclined. The phlebotomist inspects the arm to locate a suitable vein, typically in the antecubital fossa (the crease of the elbow).
• Aseptic Technique: The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) and allowed to air dry to prevent specimen contamination or hemolysis.
• Venipuncture and Sample Collection: A tourniquet is applied briefly above the collection site to make the vein more visible. A sterile, single-use needle is inserted into the vein. For coagulation assays (Factor V Activity), the blood is collected into a light blue-top tube containing 3.2% buffered sodium citrate. Precise filling of this tube is mandatory to maintain the correct 9:1 blood-to-anticoagulant ratio. For genetic testing (Factor V Leiden), a lavender-top tube containing EDTA is typically used.
• Post-Collection Care: Once the required volume of blood is collected, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile gauze pad to prevent hematoma formation. A small adhesive bandage is then applied.
• Sample Processing: The sodium citrate tube is gently inverted 3 to 4 times immediately after collection to ensure thorough mixing with the anticoagulant. It is then promptly transported to the laboratory, where it is centrifuged at high speeds to obtain platelet-poor plasma, which is essential for accurate coagulation testing.

When is a Factor V Test Performed?

Investigating Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Physicians frequently request a Factor V Leiden genetic test or Factor V activity evaluation when a patient presents with symptoms of venous thromboembolism (VTE) without an obvious provoking factor. Symptoms of DVT include unilateral leg swelling, warmth, redness, and localized pain, while PE presents with sudden shortness of breath, chest pain, and rapid heart rate. Identifying a Factor V Leiden mutation or abnormal Factor V activity helps clinicians determine the underlying cause of the clot, assess the risk of recurrence, and decide on the appropriate duration and intensity of long-term anticoagulant therapy.

Evaluating Recurrent Pregnancy Loss

Recurrent miscarriage, defined as two or more consecutive pregnancy losses, is a deeply distressing clinical issue that warrants a thorough thrombophilia workup. The Factor V Leiden mutation is a recognized genetic risk factor associated with placental thrombosis, placental insufficiency, preeclampsia, and intrauterine growth restriction (IUGR). Obstetricians request this test for women with a history of unexplained pregnancy loss or severe gestational complications to determine if thromboprophylaxis, such as low-molecular-weight heparin, is indicated in subsequent pregnancies to improve maternal and fetal outcomes.

Screening for Inherited Thrombophilia

A Factor V Leiden test is highly indicated for individuals who have a strong family history of premature venous thromboembolism (occurring before the age of 50) or known hereditary clotting disorders. Since the mutation is inherited in an autosomal dominant fashion, identifying the genetic status (heterozygous or homozygous) of asymptomatic family members allows healthcare providers to offer personalized counseling regarding high-risk situations, such as major surgeries, prolonged immobilization, or the use of estrogen-containing oral contraceptives, which can exponentially increase clot risks.

Diagnosing Unexplained Bleeding or Prolonged Clotting Times

When a patient exhibits signs of a bleeding disorder, such as easy bruising, frequent nosebleeds (epistaxis), heavy menstrual bleeding (menorrhagia), or excessive bleeding after minor surgical procedures, a Factor V Activity Assay is performed. This is especially true when initial screening tests, such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT), are prolonged. Measuring specific Factor V activity levels helps hematologists diagnose congenital Factor V deficiency (parahemophilia) or detect acquired inhibitors directed against Factor V, guiding targeted replacement therapies.

Assessing Liver Function and Coagulation Factor Deficiencies

Because Factor V is synthesized almost exclusively by hepatocytes, its activity level serves as a highly sensitive marker of hepatic synthetic function. In patients with acute liver failure, chronic cirrhosis, or severe hepatitis, physicians monitor Factor V levels alongside other coagulation factors to assess the severity of liver damage and predict clinical outcomes. Unlike other vitamin K-dependent clotting factors (such as Factors II, VII, IX, and X), Factor V synthesis does not require vitamin K, making it an invaluable tool to differentiate between vitamin K deficiency and true hepatic parenchymal dysfunction.

What Does a Factor V Test Detect?

The Factor V test is highly sensitive and capable of detecting a wide range of congenital, acquired, genetic, and functional abnormalities within the coagulation system. Specifically, the test can detect:

• Congenital Factor V Deficiency: A rare autosomal recessive bleeding disorder characterized by significantly reduced Factor V activity levels, leading to mild-to-severe bleeding manifestations.
• Factor V Leiden Mutation (Heterozygous): The presence of one mutated copy of the F5 gene, which increases the lifetime risk of developing a blood clot by approximately 3 to 8 times.
• Factor V Leiden Mutation (Homozygous): The presence of two mutated copies of the F5 gene, which dramatically escalates the risk of venous thromboembolism by up to 80 times.
• Acquired Factor V Inhibitors: Autoantibodies that neutralize Factor V activity, often arising after exposure to bovine thrombin, certain medications, autoimmune diseases, or malignancies.
• Hepatic Synthetic Dysfunction: Decreased Factor V production due to parenchymal liver diseases such as cirrhosis, toxic hepatitis, or acute liver necrosis.
• Disseminated Intravascular Coagulation (DIC): Rapid consumption of Factor V along with other clotting factors and platelets during systemic, uncontrolled coagulation activation.
• Activated Protein C Resistance (APCR): A functional impairment where the patient’s clotting system fails to respond normally to the anticoagulant effects of Activated Protein C, highly suggestive of Factor V Leiden.
• Vitamin K Deficiency Differentiation: Normal Factor V levels in the presence of decreased vitamin K-dependent factors help confirm dietary deficiency or malabsorption rather than liver failure.
• Hypercoagulability Risk: Elevated Factor V activity levels, which may transiently occur in acute phase reactions, pregnancy, or inflammatory states, slightly increasing thrombotic risk.
• Dilutional Coagulopathy: Reduced Factor V levels resulting from massive blood transfusions or fluid resuscitation without adequate replacement of fresh frozen plasma.
• Primary Fibrinolysis: Accelerated degradation of Factor V by plasmin in rare hyperfibrinolytic states.
• Asymptomatic Carrier Status: Identification of genetic carriers of the Factor V Leiden mutation who may require prophylactic measures during high-risk medical events.
• Efficacy of Anticoagulant Therapy: Baseline assessment before initiating long-term anticoagulation or evaluating treatment failure in recurrent thrombosis.
• Risk Factor for Estrogen Therapy: Increased susceptibility to thrombosis in women using oral contraceptives or hormone replacement therapy who carry the Factor V Leiden mutation.
• Placental Pathology Risk: Association with microvascular thrombosis in the placenta, contributing to adverse pregnancy outcomes.
• Post-Surgical Thrombotic Risk: Elevated risk of postoperative deep vein thrombosis in patients with underlying Factor V mutations.
• Malignancy-Associated Thrombosis: Assessment of hypercoagulable states in patients with underlying solid tumors or hematological malignancies.
• Neonatal Purpura Fulminans Risk: Severe thrombotic complications in newborns carrying homozygous mutations or combined thrombophilias.
• Pediatric Stroke Etiology: Evaluation of genetic risk factors in children presenting with unexplained arterial or venous ischemic strokes.
• Renal Vein Thrombosis Risk: Assessment of localized thrombotic events in patients with nephrotic syndrome or predisposing genetic mutations.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized across Pakistan for its commitment to providing rapid, highly accurate, and easily accessible diagnostic reports. The turnaround time (TAT) for a Factor V test depends on the specific methodology requested. Standard Factor V Activity Assays, which are performed using automated coagulation analyzers, are typically completed within 24 to 48 hours. Molecular genetic testing for the Factor V Leiden mutation, which requires advanced polymerase chain reaction (PCR) amplification and analysis, may take between 3 to 5 working days due to the complex nature of DNA extraction and genetic sequencing.

Patients can access their diagnostic reports through multiple convenient digital channels. Once the results are verified by a consultant pathologist, Chughtai Lab sends an automated SMS notification containing a direct link to download the report. Patients can also access their secure electronic health records by visiting the official Chughtai Lab website and entering their unique patient ID and password, or by utilizing the user-friendly Chughtai Lab Mobile App. Physical copies of the reports can be collected from any of the numerous Chughtai Lab collection centers located in Lahore, Karachi, Islamabad, Rawalpindi, Peshawar, Multan, Faisalabad, and other major cities across Pakistan.

Factor V Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor V Activity Assay	50% to 150% of normal activity	< 50% (Deficiency, liver disease, DIC, or acquired inhibitors); > 150% (Acute phase reactant, hypercoagulability)
Factor V Leiden Mutation (PCR)	Negative (Wild Type / No mutation detected)	Heterozygous (One mutated allele); Homozygous (Two mutated alleles)
Activated Protein C Resistance (APCR) Ratio	> 2.0 (Normal sensitivity to APC)	< 2.0 (Resistance to APC, highly correlated with Factor V Leiden mutation)
Prothrombin Time (PT)	11.0 to 13.5 seconds (Normal range)	Prolonged PT (Seen in severe Factor V deficiency, liver failure, or DIC)
Activated Partial Thromboplastin Time (aPTT)	25.0 to 35.0 seconds (Normal range)	Prolonged aPTT (Seen in Factor V deficiency, lupus anticoagulants, or heparin therapy)
Mixing Studies (PT/aPTT)	Correction to normal range upon mixing with normal plasma	Failure to correct (Indicates the presence of a specific Factor V inhibitor or non-specific anticoagulant)
Liver Function Correlation (ALT/AST/Albumin)	Normal liver enzymes and synthetic markers	Elevated enzymes and low albumin with decreased Factor V (Confirms hepatic parenchymal disease)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Factor V Test?

• Accredited Pathology Laboratories: Chughtai Lab operates under strict international quality standards, ensuring maximum precision and reliability in all hematological and molecular assays.
• Advanced Molecular Diagnostics: The laboratory utilizes cutting-edge PCR technology for the precise detection of the Factor V Leiden genetic mutation.
• Highly Qualified Pathologists: Reports are reviewed and signed by experienced consultant hematopathologists and molecular biologists.
• Convenient Home Sample Collection: Patients can schedule a professional phlebotomist to collect blood samples from the comfort of their homes across Pakistan.
• Extensive Network: With hundreds of collection centers in major cities like Lahore, Karachi, and Islamabad, accessing diagnostic services is highly convenient.
• State-of-the-Art Coagulation Analyzers: Chughtai Lab uses fully automated, high-throughput analyzers that minimize human error and deliver precise results.
• Easy Digital Report Access: Patients can view, download, and share their reports instantly via the Chughtai Lab mobile app or official website.
• Patient-Centric Care: The laboratory staff is trained to provide a compassionate, comfortable, and hygienic environment for all patients during sample collection.